The intrinsic physical and radiobiological characteristics of High Dose Rate Brachytherapy (HDR-BT) are well suited to the treatment of prostate cancer.
HDR-BT was initially used as a boost to external beam brachytherapy, but has subsequently been employed as the sole treatment, which is termed HDR monotherapy. This review summarizes the clinical outcomes and toxicity results of the principal studies and discusses the radiobiological basis supporting its use.
Written by:
De Bari B, Daidone A, Alongi F. Are you the author?
Radiation Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland; Radiation Oncology Department, University of Palermo, Palermo, Italy; Radiation Oncology Department, Sacro Cuore-Don Calabria Hospital, Negrar-Verona, Italy.
Reference: Crit Rev Oncol Hematol. 2015 Jun;94(3):360-370.
doi: 10.1016/j.critrevonc.2015.02.003
PubMed Abstract
PMID: 25819287